treatment

WORK Medical Grants East China Exclusive Distribution Rights for AI-Automated Blood Cell Morphology Analyzer, Sets RMB10 Million Sales Target for 2026

Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or…

7 days ago

Best Semaglutide For Weight Loss 2026: Is MEDVi the Best GLP-1 Supplier for a Sustainable Online Weight Loss Program?

New York City, NY, Dec. 27, 2025 (GLOBE NEWSWIRE) -- Intro As medical weight loss continues to evolve in 2026,…

1 week ago

Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support

LAS VEGAS, Dec. 24, 2025 (GLOBE NEWSWIRE) -- This holiday season, addiction experts at Desert Hope Treatment Center are encouraging individuals…

1 week ago

U.S. FDA Approves Agios AQVESME (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemiaMarketed under AQVESME brand name…

2 weeks ago

SAFE, SPONSOR OF THE 12TH MAMMI INTERNATIONAL CONFERENCE IN ITALY

SAFE, SPONSOR OF THE 12TH MAMMI INTERNATIONAL CONFERENCE IN ITALY Presentation of its Sycamore technology during a live surgical procedure…

2 weeks ago

Neuraxpharm Goes Live with TraceLink MINT to Standardize RealTime Data Exchange Across Its Global Supply Chain Network

The European specialty pharmaceutical company establishes a unified digital data foundation to enable future agentic orchestrationBOSTON, Dec. 18, 2025 /PRNewswire/…

2 weeks ago

Latest Data of InnoCares Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

December 08, 2025 21:04 ET  | Source: InnoCare Pharma BEIJING, Dec. 08, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969;…

4 weeks ago

ASH 2025 | Updated Data for Ascentage Pharmas Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended…

4 weeks ago

Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia

Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm…

4 weeks ago